Clearside Biomedical Says ODYSSEY Phase 2b Trial Of CLS-AX (Axitinib Injectable Suspension) For Neovascular Age-related Macular Degeneration Achieved Both Its Primary And Secondary Outcomes
Portfolio Pulse from Benzinga Newsdesk
Clearside Biomedical's ODYSSEY Phase 2b trial of CLS-AX for neovascular age-related macular degeneration achieved its primary and secondary outcomes, maintaining stable visual acuity and anatomical control over 9 months with a positive safety profile. 67% of participants did not require additional treatment for up to 6 months, reducing treatment burden by 84%.
October 09, 2024 | 10:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clearside Biomedical's ODYSSEY Phase 2b trial of CLS-AX achieved its primary and secondary outcomes, showing potential for reduced treatment burden in neovascular AMD with a positive safety profile.
The successful outcomes of the ODYSSEY Phase 2b trial for CLS-AX, including stable visual acuity and reduced treatment burden, are likely to positively impact Clearside Biomedical's stock price. The positive safety profile and significant reduction in treatment burden enhance the potential marketability of CLS-AX, making it an attractive option for patients and healthcare providers.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100